Braitsch, K.; Jeske, S.D.; Stroh, J.; Hefter, M.; Platen, L.; Bachmann, Q.; Renders, L.; Protzer, U.; Götze, K.S.; Herhaus, P.;
et al. Tixagevimab/Cilgavimab for COVID-19 Pre-Exposure Prophylaxis in Hematologic Patients—A Tailored Approach Based on SARS-CoV-2 Vaccine Response. Vaccines 2024, 12, 871.
https://doi.org/10.3390/vaccines12080871
AMA Style
Braitsch K, Jeske SD, Stroh J, Hefter M, Platen L, Bachmann Q, Renders L, Protzer U, Götze KS, Herhaus P,
et al. Tixagevimab/Cilgavimab for COVID-19 Pre-Exposure Prophylaxis in Hematologic Patients—A Tailored Approach Based on SARS-CoV-2 Vaccine Response. Vaccines. 2024; 12(8):871.
https://doi.org/10.3390/vaccines12080871
Chicago/Turabian Style
Braitsch, Krischan, Samuel D. Jeske, Jacob Stroh, Maike Hefter, Louise Platen, Quirin Bachmann, Lutz Renders, Ulrike Protzer, Katharina S. Götze, Peter Herhaus,
and et al. 2024. "Tixagevimab/Cilgavimab for COVID-19 Pre-Exposure Prophylaxis in Hematologic Patients—A Tailored Approach Based on SARS-CoV-2 Vaccine Response" Vaccines 12, no. 8: 871.
https://doi.org/10.3390/vaccines12080871
APA Style
Braitsch, K., Jeske, S. D., Stroh, J., Hefter, M., Platen, L., Bachmann, Q., Renders, L., Protzer, U., Götze, K. S., Herhaus, P., Verbeek, M., Spinner, C. D., Bassermann, F., Högner, M., Haller, B., Schneider, J., & Heider, M.
(2024). Tixagevimab/Cilgavimab for COVID-19 Pre-Exposure Prophylaxis in Hematologic Patients—A Tailored Approach Based on SARS-CoV-2 Vaccine Response. Vaccines, 12(8), 871.
https://doi.org/10.3390/vaccines12080871
